Related Experiment Video

Updated: May 22, 2026

Multicellular Human Alveolar Model Composed of Epithelial Cells and Primary Immune Cells for Hazard Assessment
09:27

Multicellular Human Alveolar Model Composed of Epithelial Cells and Primary Immune Cells for Hazard Assessment

Published on: May 6, 2020

[Hepatitis B immunization in the neonate and the immunocompromised: time to resort to dedicated teams?]

N Boillat Blanco1, O Manuel, B Vaudaux

  • 1Service des maladies infectieuses, CHUV, 1011 Lausanne. noemie.boillat@chuv.ch

Revue Medicale Suisse
|May 23, 2012
PubMed

Insights

Hepatitis B vaccination is crucial for immunocompromised individuals and infants born to infected mothers, but coverage remains low. Dedicated teams can improve vaccine uptake in these vulnerable populations.

Area of Science:

  • Immunology
  • Public Health
  • Infectious Diseases

Background:

  • Hepatitis B virus (HBV) infection poses severe risks to vulnerable populations, including the immunocompromised and infants of chronically infected mothers.
  • Current vaccination recommendations target these high-risk groups, yet vaccine coverage remains suboptimal, leading to incomplete protection.

Purpose of the Study:

  • To highlight the critical need for improved hepatitis B vaccine coverage in vulnerable patient groups.
  • To emphasize the importance of a systematic approach to hepatitis B prevention strategies.

Main Methods:

  • Review of existing studies and clinical guidelines concerning hepatitis B vaccination in at-risk populations.
  • Analysis of factors contributing to suboptimal vaccine uptake and the impact of targeted interventions.

Main Results:

  • Studies indicate that dedicated nursing or medical teams can significantly increase hepatitis B vaccine coverage.
  • A systemic and meticulous management approach is essential for effective prevention in vulnerable patients.

Conclusions:

  • Enhanced hepatitis B vaccine coverage is achievable through structured, team-based management strategies.
  • Implementing dedicated teams for preventive measures is recommended to optimize protection against hepatitis B in vulnerable individuals.

More Related Videos

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Vaccinations01:51

Vaccinations

Overview
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...